
The global Celecoxib market size was valued at US$ 1243.6 million in 2023. With growing demand in downstream market, the Celecoxib is forecast to a readjusted size of US$ 2232 million by 2030 with a CAGR of 8.7% during review period.
The research report highlights the growth potential of the global Celecoxib market. Celecoxib are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Celecoxib. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Celecoxib market.
Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
Key Features:
The report on Celecoxib market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Celecoxib market. It may include historical data, market segmentation by Type (e.g., 50mg, 100mg), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Celecoxib market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Celecoxib market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Celecoxib industry. This include advancements in Celecoxib technology, Celecoxib new entrants, Celecoxib new investment, and other innovations that are shaping the future of Celecoxib.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Celecoxib market. It includes factors influencing customer ' purchasing decisions, preferences for Celecoxib product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Celecoxib market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Celecoxib market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Celecoxib market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Celecoxib industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Celecoxib market.
Market Segmentation:
Celecoxib market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
50mg
100mg
200mg
400mg
Segmentation by application
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Other diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine
Key Questions Addressed in this Report
What is the 10-year outlook for the global Celecoxib market?
What factors are driving Celecoxib market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Celecoxib market opportunities vary by end market size?
How does Celecoxib break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Celecoxib Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Celecoxib by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Celecoxib by Country/Region, 2019, 2023 & 2030
2.2 Celecoxib Segment by Type
2.2.1 50mg
2.2.2 100mg
2.2.3 200mg
2.2.4 400mg
2.3 Celecoxib Sales by Type
2.3.1 Global Celecoxib Sales Market Share by Type (2019-2024)
2.3.2 Global Celecoxib Revenue and Market Share by Type (2019-2024)
2.3.3 Global Celecoxib Sale Price by Type (2019-2024)
2.4 Celecoxib Segment by Application
2.4.1 Rheumatoid arthritis
2.4.2 osteoarthritis
2.4.3 Acute pain
2.4.4 Musculoskeletal pain
2.4.5 Other diseases
2.5 Celecoxib Sales by Application
2.5.1 Global Celecoxib Sale Market Share by Application (2019-2024)
2.5.2 Global Celecoxib Revenue and Market Share by Application (2019-2024)
2.5.3 Global Celecoxib Sale Price by Application (2019-2024)
3 Global Celecoxib by Company
3.1 Global Celecoxib Breakdown Data by Company
3.1.1 Global Celecoxib Annual Sales by Company (2019-2024)
3.1.2 Global Celecoxib Sales Market Share by Company (2019-2024)
3.2 Global Celecoxib Annual Revenue by Company (2019-2024)
3.2.1 Global Celecoxib Revenue by Company (2019-2024)
3.2.2 Global Celecoxib Revenue Market Share by Company (2019-2024)
3.3 Global Celecoxib Sale Price by Company
3.4 Key Manufacturers Celecoxib Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Celecoxib Product Location Distribution
3.4.2 Players Celecoxib Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Celecoxib by Geographic Region
4.1 World Historic Celecoxib Market Size by Geographic Region (2019-2024)
4.1.1 Global Celecoxib Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Celecoxib Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Celecoxib Market Size by Country/Region (2019-2024)
4.2.1 Global Celecoxib Annual Sales by Country/Region (2019-2024)
4.2.2 Global Celecoxib Annual Revenue by Country/Region (2019-2024)
4.3 Americas Celecoxib Sales Growth
4.4 APAC Celecoxib Sales Growth
4.5 Europe Celecoxib Sales Growth
4.6 Middle East & Africa Celecoxib Sales Growth
5 Americas
5.1 Americas Celecoxib Sales by Country
5.1.1 Americas Celecoxib Sales by Country (2019-2024)
5.1.2 Americas Celecoxib Revenue by Country (2019-2024)
5.2 Americas Celecoxib Sales by Type
5.3 Americas Celecoxib Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Celecoxib Sales by Region
6.1.1 APAC Celecoxib Sales by Region (2019-2024)
6.1.2 APAC Celecoxib Revenue by Region (2019-2024)
6.2 APAC Celecoxib Sales by Type
6.3 APAC Celecoxib Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Celecoxib by Country
7.1.1 Europe Celecoxib Sales by Country (2019-2024)
7.1.2 Europe Celecoxib Revenue by Country (2019-2024)
7.2 Europe Celecoxib Sales by Type
7.3 Europe Celecoxib Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Celecoxib by Country
8.1.1 Middle East & Africa Celecoxib Sales by Country (2019-2024)
8.1.2 Middle East & Africa Celecoxib Revenue by Country (2019-2024)
8.2 Middle East & Africa Celecoxib Sales by Type
8.3 Middle East & Africa Celecoxib Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Celecoxib
10.3 Manufacturing Process Analysis of Celecoxib
10.4 Industry Chain Structure of Celecoxib
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Celecoxib Distributors
11.3 Celecoxib Customer
12 World Forecast Review for Celecoxib by Geographic Region
12.1 Global Celecoxib Market Size Forecast by Region
12.1.1 Global Celecoxib Forecast by Region (2025-2030)
12.1.2 Global Celecoxib Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Celecoxib Forecast by Type
12.7 Global Celecoxib Forecast by Application
13 Key Players Analysis
13.1 Pfizer Inc
13.1.1 Pfizer Inc Company Information
13.1.2 Pfizer Inc Celecoxib Product Portfolios and Specifications
13.1.3 Pfizer Inc Celecoxib Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Inc Main Business Overview
13.1.5 Pfizer Inc Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Celecoxib Product Portfolios and Specifications
13.2.3 Teva Celecoxib Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 Mylan
13.3.1 Mylan Company Information
13.3.2 Mylan Celecoxib Product Portfolios and Specifications
13.3.3 Mylan Celecoxib Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Mylan Main Business Overview
13.3.5 Mylan Latest Developments
13.4 Apotex
13.4.1 Apotex Company Information
13.4.2 Apotex Celecoxib Product Portfolios and Specifications
13.4.3 Apotex Celecoxib Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Apotex Main Business Overview
13.4.5 Apotex Latest Developments
13.5 Lupin
13.5.1 Lupin Company Information
13.5.2 Lupin Celecoxib Product Portfolios and Specifications
13.5.3 Lupin Celecoxib Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Lupin Main Business Overview
13.5.5 Lupin Latest Developments
13.6 Hengrui Medicine
13.6.1 Hengrui Medicine Company Information
13.6.2 Hengrui Medicine Celecoxib Product Portfolios and Specifications
13.6.3 Hengrui Medicine Celecoxib Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Hengrui Medicine Main Business Overview
13.6.5 Hengrui Medicine Latest Developments
14 Research Findings and Conclusion
Ìý
Ìý
*If Applicable.
